SCHEMBL4208306

SCHEMBL4208306

CCN(CCCCCCNC(=O)OCc1ccccc1)Cc1ccccc1OC

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.64
BCHE P06276 11/20 0.60
ACHE P22303 11/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207014 1.00 APP (0.64) APPBCHEACHE
SCHEMBL4365126 1.00 APP (0.64) APPBCHEACHE
SCHEMBL4204714 0.99 APP (0.64) APPBCHEACHE
SCHEMBL4371553 0.96 APP (0.63) APPBCHEACHE
SCHEMBL4375004 0.92 APP (0.54) APPBCHEACHE
SCHEMBL4364532 0.88 APP (0.63) APPBCHEACHE
SCHEMBL4203085 0.88 TGM2 (0.54) APPBCHEACHE
SCHEMBL4365817 0.87 APP (0.63) APPBCHEACHE
SCHEMBL4376555 0.87 BCHE (0.54) APPBCHEACHE
SCHEMBL4367367 0.86 APP (0.73) APPBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589219-B2 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) 2009-09-15 US disclosed
US-7589219-B2 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) 2009-09-15 US disclosed
US-20090093521-A1 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives ALMA MATER STUDIORUM - UNIVERISTA'DI BOLOGNA (IL) 2009-04-09 US disclosed
US-20090093521-A1 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives ALMA MATER STUDIORUM - UNIVERISTA'DI BOLOGNA (IL) 2009-04-09 US disclosed
EP-1890995-A2 SYNTHESIS OF ORGANIC COMPOUNDS Alma Mater Studiorum -Universita' di Bologna (IT) 2008-02-27 EP disclosed
WO-2006134457-A2 2,5-BIS-DIAMIMNE [1 , 4] BENZOQUINONE-DERIVATIVES ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) 2006-12-21 WO disclosed
US-20050261345-A1 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261345-A1 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor PSEN2, BACE2, WEE2 APP 16/4885BCHE 77/4885ACHE 169/4885
US-20090093521-A1 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives POLQ, DDX5, SDHA APP 3616/4885BCHE 2356/4885ACHE 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.